Research needed to improve targeted radionuclide therapy as cancer treatments

Targeted radionuclide therapy (TRT) has the potential to significantly improve cancer treatments, particularly for cancer that has spread throughout the body or has become resistant to other therapies. However, we need to complete more research, especially in the field of radiobiology and dosimetry, in order for TRT to reach its full potential.

We have outlined several opportunities to develop a deeper understanding of the radiobiology and dosimetry of TRT through collaborations between researchers and institutions in the United Kingdom and Netherlands in our new white paper, which you can download now.

The UK and Netherlands are already at the forefront of TRT research, but there is more that we can do to improve on current therapies and make them more cost-efficient. We have an opportunity to use patient-driven science to optimise patient care and personalise treatments, but to do that we need to strategically allocate funding, facilitate more UK-NL clinical trials and coordinate training initiatives.

We believe that by creating a deeper evidence base using radiobiology and dosimetry knowledge, we can develop better clinical implementation of TRT, and improve clinical outcomes in terms of survival rates and quality of life.

Please share our white paper with your colleagues and networks, as well as on social media. If you’re working in this area or have had some input into TRT, please also share it with your institutional communications team and ask them to post about it on their social platforms. In order to convince policy makers and funders to invest in TRT, we need to make a splash!

We would also like to invite you to provide an endorsement by filling in the form on our download page, where you can opt in to updates on this project, as we have them.